Autism and associated disorders: cannabis as a potential therapy

Babayeva, Mariana; Assefa, Haregewein; Basu, Paramita; Loewy, Zvi G.

doi:10.31083/j.fbe1401001

Cited by 11 publications

(34 citation statements)

References 290 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…from infancy to adulthood) and are accompanied by changes in CB1R activity in the amygdala, hippocampus, and dorsal striatum – all areas that contribute to socio-emotional processing (Servadio et al, 2016 ). While pharmacological intervention with URB597 or PF-3845 to modulate AEA reversed social impairments, FAAH inhibition also increases PEA and OEA, enhancing the activity of hippocampal CB1Rs and effecting cognition (Babayeva, Assefa, Basu, & Loewy, 2022 ; Kerr et al, 2013 ; Kerr, Gilmartin, & Roche, 2016 ; Servadio et al, 2016 ; Trezza et al, 2012 ; Trezza & Vanderschuren, 2008 ). In sum, the VPA models replicate data in other ASD animal models linking AEA signaling and social functioning and expand what is known by providing important considerations regarding the impact of development on AEA modulation.…”

Section: Autism Spectrum Disordermentioning

confidence: 99%

The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses

Hill,

Haney,

Hillard

et al. 2023

Psychol. Med.

View full text Add to dashboard Cite

Cannabis is well established to impact affective states, emotion and perceptual processing, primarily through its interactions with the endocannabinoid system. While cannabis use is quite prevalent in many individuals afflicted with psychiatric illnesses, there is considerable controversy as to whether cannabis may worsen these conditions or provide some form of therapeutic benefit. The development of pharmacological agents which interact with components of the endocannabinoid system in more localized and discrete ways then via phytocannabinoids found in cannabis, has allowed the investigation if direct targeting of the endocannabinoid system itself may represent a novel approach to treat psychiatric illness without the potential untoward side effects associated with cannabis. Herein we review the current body of literature regarding the various pharmacological tools that have been developed to target the endocannabinoid system, their impact in preclinical models of psychiatric illness and the recent data emerging of their utilization in clinical trials for psychiatric illnesses, with a specific focus on substance use disorders, trauma-related disorders, and autism. We highlight several candidate drugs which target endocannabinoid function, particularly inhibitors of endocannabinoid metabolism or modulators of cannabinoid receptor signaling, which have emerged as potential candidates for the treatment of psychiatric conditions, particularly substance use disorder, anxiety and trauma-related disorders and autism spectrum disorders. Although there needs to be ongoing clinical work to establish the potential utility of endocannabinoid-based drugs for the treatment of psychiatric illnesses, the current data available is quite promising and shows indications of several potential candidate diseases which may benefit from this approach.

show abstract

Section: Autism Spectrum Disordermentioning

confidence: 99%

The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses

Hill,

Haney,

Hillard

et al. 2023

Psychol. Med.

View full text Add to dashboard Cite

show abstract

“…Cannabis has a wide range of clinical applications and the list of diseases in which cannabis/cannabinoids are used as a treatment is constantly increasing. Studies in experimental models and humans have suggested anti-inflammatory, neuroprotective, anxiolytic, and antipsychotic properties of chemicals extracted from cannabis [ 4 ]. Cannabis contains more than 100 cannabinoids, where CBD and THC are the subjects of most studies [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…CBD decreases THC psychoactivity and exhibits anti-inflammatory, antioxidant, anticonvulsant, and neuroprotective effects [ 6 , 9 , 10 , 11 ]. CBD (Epidiolex) has been FDA and EMA approved for Dravet and Lennox–Gastaut syndromes [ 4 ]. Another cannabis medication, Sativex (THC:CBD, 1:1 ratio), is used to treat symptoms of multiple sclerosis [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…CBD (Epidiolex) has been FDA and EMA approved for Dravet and Lennox–Gastaut syndromes [ 4 ]. Another cannabis medication, Sativex (THC:CBD, 1:1 ratio), is used to treat symptoms of multiple sclerosis [ 4 ]. Moreover, a synthetic pharmaceutical-grade THC (dronabinol and nabilone) has been FDA approved for the treatment of chemotherapy-induced nausea and vomiting in patients who failed to respond to traditional antiemetic therapy.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabis Pharmacogenomics: A Path to Personalized Medicine

Babayeva

Loewy

2023

CIMB

Self Cite

View full text Add to dashboard Cite

Cannabis and related compounds have created significant research interest as a promising therapy in many disorders. However, the individual therapeutic effects of cannabinoids and the incidence of side effects are still difficult to determine. Pharmacogenomics may provide the answers to many questions and concerns regarding the cannabis/cannabinoid treatment and help us to understand the variability in individual responses and associated risks. Pharmacogenomics research has made meaningful progress in identifying genetic variations that play a critical role in interpatient variability in response to cannabis. This review classifies the current knowledge of pharmacogenomics associated with medical marijuana and related compounds and can assist in improving the outcomes of cannabinoid therapy and to minimize the adverse effects of cannabis use. Specific examples of pharmacogenomics informing pharmacotherapy as a path to personalized medicine are discussed.

show abstract

“…We invite our readers to update their general views by reading, for example, the following review papers by Kirkland et al (2022) and Bilbao and Spanagel (2022). Remarkably, the majority of these reviews published in 2022 (about 15%) discuss the therapeutic role of CBD in autism spectrum disorders (ASD), revealing an emerging trend (Aishworiya et al, 2022;Babayeva et al, 2022;Brignell et al, 2022;Colizzi et al, 2022;de Camargo et al, 2022;Dias-de Freita et al, 2022;Pedrazzi et al, 2022;.…”

mentioning

confidence: 99%

Editorial: Cannabidiol treatment in neurotherapeutic interventions, volume II

González-Cuevas

Navarrete²,

García-Gutiérrez³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Editorial on the Research Topic Cannabidiol treatment in neurotherapeutic interventions, volume IIIn this Research Topic, "Cannabidiol Treatment in Neurotherapeutic Interventions, Volume II", we have compiled a new series of case and research reports and original research articles written by world-renowned experts in the field of neuropsychopharmacology. These publications provide scientifically sound evidence in the evaluation of cannabidiol (CBD) as a potential pharmacotherapeutic tool for the treatment of mood disorders such as anxiety and depression and diseases such as Alzheimer's and Parkinson's in animal and human studies. Furthermore, a wide variety of methodologies, ranging from novel analytical and computational techniques to a medical case, also cast light on CBD's underlying action mechanisms, therapeutic monitoring, and potential side effect profile.In a 3-month follow-up observational and clinical trial study, Souza et al. reported the anxiolytic effects of CBD in frontline healthcare professionals that lasted up to a month after treatment discontinuation. In newborn piglets, Barata et al. demonstrated that CBD can prevent hypoxia-ischemia-induced mood disturbances by acting on 5hydrotryptamine 1A (5HT 1A ) receptors. In aged rats, Hernandez-Hernandez and Garcia-Fuster demonstrated a dose-dependent antidepressant-like response for CBD. In a female Alzheimer's disease mouse model, Chesworth et al. showed a beneficial effect of long-term CBD on learning and anxiety. Regarding the role of CBD in Parkinson's disease, Patricio et al. demonstrated that intrapallidal injection of CBD had inhibitory effects on G protein-coupled receptor 55 (GPR55) receptors in the external globus pallidus, seemingly related to GABAergic overactivation in hemiparkinsonism, and Morash et al. showed that minimum essential therapeutic mixtures from the cannabis plant extracts, including CBD, had the greatest therapeutic potential for treating Parkinson's disease using in silico, in vitro, and medium in vivo experimental systems. Using computational models, Davila et al. found interacting loci in the

show abstract

Autism and associated disorders: cannabis as a potential therapy

Cited by 11 publications

References 290 publications

The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses

The endocannabinoid system as a putative target for the development of novel drugs for the treatment of psychiatric illnesses

Cannabis Pharmacogenomics: A Path to Personalized Medicine

Editorial: Cannabidiol treatment in neurotherapeutic interventions, volume II

Contact Info

Product

Resources

About